In prostate cancer, mutations of KMT2 genes (also known as mixed lineage leukemia family methylates) and dysregulation of EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) and LSD1 (lysine-specific demethylase 1, also known as KDM1A) are commonly observed and further enriched in CRPC (5, 12). The gene discussed is EZH2; the disease is prostate carcinoma.